Skip to main content
. Author manuscript; available in PMC: 2020 Jun 29.
Published in final edited form as: J Immunother. 2010 Oct;33(8):828–833. doi: 10.1097/CJI.0b013e3181eec14c

FIGURE 2.

FIGURE 2.

Overall survival of patients on trial. One patient is lost to follow-up after progression of disease at 12 weeks. Many patients entered with metastatic disease receiving Ipilimumab as second line therapy. Short survival is characteristic for these patients.